FDA appears to be acting more like a development partner than a regulator in dealing with a “breakthrough” therapy designee, based on the experience of one sponsor.
Pharmacyclics Inc. Chief Medical Officer Lori Kunkel said early discussions about ibrutinib, which holds multiple designations, offer a better understanding for sponsors of regulatory expectations through more and easier access to FDA reviewers and earlier discussions of trial designs and other issues
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?